Insights about U.S. Stocks from mix sectors that landed in the Green-Zone in the course of Tuesday’s trade, are depicted underneath:
Peregrine Pharmaceuticals (NASDAQ:PPHM)’s shares picked up 5.71%, and closed at $1.48, during the last trading session.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical corporation focused on advancing bavituximab, a novel immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, towards commercialization and providing integrated cGMP clinical and commercial bio-manufacturing services, declared that Steven W. King, president and chief executive officer, will present a corporation update at the 27th Annual ROTH Conference on Monday, March 9th, 2015 at 10:00 AM Pacific Time (1:00 PM Eastern Time) at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical corporation, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer together with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.
Gogo Inc (NASDAQ:GOGO), raised 5.64%, and closed at $19.47.
Gogo Inc. declared recently that it intends to offer $300 million aggregate principal amount of convertible senior notes due 2020, subject to market and other conditions, in a private offering to qualified institutional buyers following Rule 144A under the Securities Act of 1933, as amended. Gogo also anticipates to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $45 million aggregate principal amount of the notes to cover over-allotments, if any.
The notes will be convertible preceding to December 1, 2019 only under certain circumstances and thereafter at any time. Upon conversion, the notes will be settled in shares of Gogo’s ordinary stock, or, if and when Gogo receives the approval of shareholders in accordance with applicable NASDAQ rules, at Gogo’s election in shares of Gogo’s ordinary stock, cash or a combination of cash and shares of Gogo’s ordinary stock.
Gogo Inc. provides in-flight Internet connectivity and wireless in-cabin digital entertainment solutions in the United States and internationally. The corporation, through its proprietary air-to-ground (ATG) network and satellite-based technologies, offers a suite of connectivity solutions and other services, counting passenger connectivity, passenger entertainment, and operations-oriented communications services, in addition to advertising, e-commerce, content, and other offerings, such as destination-based event ticketing, flight tracker, and weather and travel sites.
CEL-SCI Corporation (NYSEMKT:CVM) enhanced 5.56%, and closed at $ 1.14.
CEL-SCI Corporation, declared that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This follows January’s preceding record. A total of 377 patients have been enrolled in the world’s largest Phase III study in head and neck cancer as of February 28, 2015.
“We are happy to have achieved this successive month of record enrollment in 2015, particularly in light of the fact that February was a shorter month. During the month of February we also had a record number of patient screenings. During the month of February we also received clearance in the Philippines, Malaysia and Belarus to start patient enrollment in those countries. This is predictable to result in an even higher number of patients being enrolled in the study in March,” stated CEL-SCI Chief Executive Officer Geert Kersten.
The aim is to enroll a total of 880 patients through about 100 clinical centers in about 25 countries by the end of 2015.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The corporation’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development contract in HIV/HPV co-infected men and women with peri-anal warts.
Laredo Petroleum Inc (NYSE:LPI), rose 5.53%, and closed at $11.84.
Laredo Petroleum, Inc., declared the pricing of an upsized underwritten public offering of 60,000,000 shares of its ordinary stock for total gross proceeds (before underwriter`s fees and estimated expenses) of about $663.0 million. The Corporation has also granted the underwriter a 30-day option to purchase up to 9,000,000 additional shares of the Corporation`s ordinary stock.
The Corporation intends to use the net proceeds from the sale of the shares of ordinary stock to repay all of its outstanding indebtedness under its senior secured credit facility and to apply the excess to capital expenditures or, subject to approval of the lenders under its senior secured credit facility, redeem a portion of the outstanding $550 million of its 9 1/2% senior unsecured notes due 2019.
The offering is predictable to close on or about March 5, 2015, subject to customary closing conditions.
Credit Suisse Securities (USA) LLC is acting as the sole book-running manager for the offering.
Laredo Petroleum, Inc. operates as an independent energy corporation in the United States. It focuses on the attainment, exploration, and development of oil and natural gas properties primarily in the Permian Basin in west Texas.
